Early days again
but any vaccine that can at least make it harder to get infected is hugely
helpful inasmuch as combined with a serious irradiation program, it can act as
a huge accelerator and a serious barrier to reinfection.
So yes this is
very promising. We are still a long way
from declaring malaria defeated, but there have been a number of local
successes that need to be built on and this type of vaccine will make the
process an order of magnitude more efficient.
We have posted
on a range of therapies out there and I must say that a solution remains fairly
elusive. As such we must remain
conservative and hopeful. At least a
victim with access to best care runs a good chance of beating this disease.
Newly-developed malaria
vaccine shows promise of providing full protection
Researchers
in the U.S. are reporting that a newly-developed vaccine against
malaria, called the PfSPZ Vaccine, is the first to show that it can provide
full protection against the illness, and it will now start clinical trials in
Africa.
Malaria is one of the top 10 most deadly diseases in the world. It's caused by a tiny parasite carried by certain types of mosquitoes, and is transmitted to humans when the mosquitoes bite us. When the parasite invades our body, it causes serious flu-like symptoms that can be fatal if not treated.
According
to the CDC (Centers
for Disease Control and Prevention), just in the year 2010 alone, there
were 219 million cases of malaria worldwide, and 660,000 of those people
infected died from the illness. The region of the world most affected by it is
Africa, which accounted for over 90 per cent of those case. By comparison, the United
States reports about 1,500 cases per year, on average, and Canada sees
around 14 cases per year.
The
malaria parasite, transmitted by mosquitoes, causes hundreds of thousands of
deaths around the world every …Up until now, there hasn't been a reliable
vaccine against the illness due to the complicated nature of the parasite —
there are four different kinds and they have an incredible ability to adapt,
thus thwarting our attempts to develop protection against it. Vaccines are made
using dead or 'inactive' versions organisms that make us sick, since those
still activate our immune systems, but using dead malaria parasites in a
vaccine doesn't work though, specifically because of this adaptability.
However,
the researchers found a way to produce parasites that were alive, so
they could still adapt, but were weakened to the point where they couldn't
actually make us sick. This would allow our immune system to develop new
antibodies as the weakened parasite adapted. One challenge that needs to be
overcome is that the vaccine needs to be given intravenously — so directly into
the blood stream. This makes it slightly limited, as it doesn't take a simple
jab in the arm to administer a dose to a patient.
"Despite
this challenge, these trial results are a promising first step in generating
high-level protection against malaria, and they allow for future studies to
optimize the dose, schedule and delivery route of the candidate vaccine,"
said Dr. Robert A. Seder, the principle investigator of the trials done at the
National Institute of Allergy and Infectious Diseases, according to a statement.
The
next stage is to start clinical trials, which will apparently be conducted at
the Ifakara Health
Institute, in Tanzania, and the researchers hope the vaccine will be
licensed and ready for use within four years.
No comments:
Post a Comment